Tag: Biotechnology
-
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
They’re the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.
-
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
-
Novo Nordisk rebrands to ‘Novo,’ unveils corporate changes as it fights for obesity market share
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
-
AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca’s peak annual sales forecast of more than $5 billion.
-
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
The string of deals builds on the Trump administration’s push to link the nation’s drug prices to cheaper ones abroad.
-
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
-
HHS plans new FDA deputy commissioner roles for technology and drugs, sources say
HHS plans to name two deputy commissioners for technology and drugs, said two sources familiar with the matter.
-
Most Americans aren’t anti-vaccine. They’re uncertain — and that’s a growing public health challenge
The bigger issue at hand may be that many Americans fall into a large, uncertain middle ground – neither firmly pro-vaccine nor staunchly opposed.
-
Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 50%
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
-
Trump wants to split the MMR vaccine. Experts say that’s unlikely — and comes with consequences
Doctors and other experts say that splitting the measles, mumps and rubella shot has no scientific basis and is unlikely to get off the ground.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany india Investment strategy iran Iran war markets People per politics return russia S&P 500 Index said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
